Congress Rejects Big Pharma Bailout

Defeat For Price-Gouging Drug Manufacturers; Victory For Taxpayers & Patients

 

For Immediate Release:
Contact: Lauren Blair
(201) 213-5004
lblair@fp1strategies.com

The Campaign for Sustainable Rx Pricing released the following statement after House and Senate Committee leaders introduced the Opioid Crisis Response Act of 2018 without changes to the Medicare Part D program, which would have handed Big Pharma a multi-billion dollar bailout at the expense of seniors and taxpayers:

“Despite Big Pharma’s best efforts to exploit the opioid crisis, this legislation is focused on helping families and communities, not enriching price-gouging drug manufacturers with a multi-billion dollar bailout. This likely won’t be the last time Big Pharma tries to use deceptive and distracting tactics this year to make money on the backs of seniors and taxpayers, which is why CSRxP will continue to fight for patients by holding Big Pharma accountable, while working with Congress and the administration on solutions that increase competition and lower prescription drug prices.”

BACKGROUND:

CSRxP worked aggressively to thwart the Big Pharma bailout from being included in the final opioids package, including launching a digital ad campaign and sending a letter with other groups representing patients, doctors, plans and health care providers to House and Senate leadership urging them to protect patients and taxpayers.

CLICK HERE to read the full letter.

###

About the Campaign for Sustainable Rx Pricing
The Campaign for Sustainable Rx Pricing (CSRxP) is a broad-based coalition of leaders – physicians, nurses, hospitals, consumers, health plans, PBMs, pharmacists, and businesses – promoting bipartisan, market-based solutions to lower drug prices in America.